| Autor: |
Troy Scroggins, John S. Bolton, Kathryn Winter, Frank A. Vicini, Julia White, Rachel Rabinovitch, Beryl McCormick, Doug Arthur, Robert R. Kuske |
| Rok vydání: |
2014 |
| Předmět: |
|
| Zdroj: |
Brachytherapy. 13:17-22 |
| ISSN: |
1538-4721 |
| DOI: |
10.1016/j.brachy.2013.08.002 |
| Popis: |
Purpose Radiation Therapy Oncology Group (RTOG) 95-17, a Phase II trial to evaluate multicatheter brachytherapy (mCathBrachy) as the sole method of radiation therapy for Stage I–II breast cancer (BrCa), was the first cooperative group trial in North America to evaluate accelerated partial breast irradiation (APBI) and include patient-reported outcomes (PROs). This report presents the year-5 toxicity and cosmesis data. Methods and Materials After lumpectomy and axillary dissection for invasive BrCa (tumor size Results Grade (G) 1–2 skin toxicity developed in 78% of the pts and G3 in 13% (no G4). The tx effects included skin dimpling/indentation (37%), fibrosis (45%), telangiectasias (45%), skin catheter marks (54%), and symptomatic fat necrosis (15%). Breast asymmetry was reported in 73%. Rates of excellent-to-good cosmesis were similar between PROs (66%) and radiation oncologists (68%). The PROs of tx satisfaction at year-5 was 75%. Conclusions RTOG 95-17 documents the year-5 skin toxicity and tx effects of mCathBrachy APBI, which are associated with PROs of good-to-excellent cosmesis and high tx satisfaction. This emphasizes the importance of PROs when assessing BrCa tx. National Surgical Adjuvant Breast and Bowel Project B39/RTOG 0413 will allow for definitive comparisons between APBI and whole breast radiation therapy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
